Keywords: all, ctcl, patients, see, response, zolinza, jco

30% of all CTCL patients see response with Zolinza, JCO study

Article | 30 July 2007

Print This

US drug major Merck & Co says that a trial of Zolinza (vorinostat) in patients with advanced, refractory cutaneous T-cell lymphoma ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in